October 16, 2009

ONO PHARMACEUTICAL CO., LTD.
President and Representative Director: Gyo Sagara,
Code No.: 4528 at the 1st section of the Tokyo / Osaka Stock Exchange
INQUIRIES: Kinya Morimoto, Managing Director, Public Relations
(Phone: 06-6263-5670)

Approval Received for Antiemetic Drug EMEND® Capsule

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced that an antiemetic drug, EMEND® Capsule 125 mg, EMEND® Capsule 80 mg, and EMEND® Capsule Set (INN: aprepitant), a selective neurokinin-1 (NK1) receptor antagonist, was approved in Japan on October 16, 2009.

The drug was originally discovered by Merck & Co., Inc., Whitehouse Station N.J. USA, and granted an exclusive license to Ono for development and commercialization in Japan in November 2004. A Japanese New Drug Application for the drug was then submitted in September 2007.

Nausea and vomiting are two common complications of cancer chemotherapy that can lead to considerable distress and disruption in patients' lives. Failure to control these complications often result in aggravation of general conditions or systemic wasting symptoms due to malnutrition and weight loss. In addition, the discomfort by chemotherapy induced nausea and vomiting may lower a patients' Quality of Life (QOL), and interfere with the continuation of chemotherapy. It is therefore extremely important in maintaining the QOL of cancer patients and continuing chemotherapy. Chemotherapy induced nausea and vomiting can occur within the first 24 hours (acute phase) and can continue for several days after that (delayed phase) following emetogenic chemotherapy. Specifically, in Japan, patients receiving such chemotherapy frequently experience these delayed complications despite the use of currently available anti-vomiting medicines.

EMEND® is the world's first selective neurokinin-1 (NK1) receptor antagonist for the prevention of these chemotherapy induced complications, and has been demonstrated in clinical trials conducted worldwide including Japan that EMEND® works to provide improved prevention against acute as well as delayed nausea and vomiting for which the existing treatments has only insufficient effect.

We are very pleased that the approval was granted and now we can provide a new treatment for patients who suffer from chemotherapy induced nausea and vomiting.

EMEND® has been approved and marketed in 70 countries and regions or more globally including the US, EU countries as of September 2009. EMEND® is recommended as a prophylactic use for nausea and vomiting caused by cancer chemotherapy in antiemetic guidelines issued by cancer associations such as the American Society of Clinical Oncology (ASCO), the Multinational Association of Supportive Care in Cancer (MASCC), and the National Comprehensive Cancer Network (NCCN).

PRODUCT SUMMARY:

Trade Name	EMEND® Capsule 125 mg, EMEND® Capsule 80 mg, EMEND® Capsule Set
Generic Name (INN)	aprepitant
Indication	Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including in delayed phase)
Dosage and Administration	For oral use, the usual adult dosage of aprepitant, in combination with other antiemetic agents, is 125 mg on Day 1 of administration of an antineoplastic agent, followed by a daily dose of 80 mg from day 2 on.